SQI Diagnostics Dirección

Dirección controles de criterios 2/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Andrew Morris

Chief Executive Officer (CEO)

CA$543.0k

Compensación total

Porcentaje del salario del CEO	73.7%
Permanencia del CEO	2yrs
Participación del CEO	0.09%
Permanencia media de la dirección	3.5yrs
Promedio de permanencia en la Junta Directiva	8.4yrs

Actualizaciones recientes de la dirección

Recent updates

If You Had Bought SQI Diagnostics (CVE:SQD) Stock A Year Ago, You Could Pocket A 246% Gain Today

Dec 22

Is SQI Diagnostics (CVE:SQD) Using Debt Sensibly?

Nov 17

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Andrew Morris en comparación con los beneficios de SQI Diagnostics?
Fecha	Compensación total	Salario	Ingresos de la empresa
Mar 31 2023	n/a	n/a	-CA$19m
Dec 31 2022	n/a	n/a	-CA$18m
Sep 30 2022	CA$543k	CA$400k	-CA$19m
Jun 30 2022	n/a	n/a	-CA$13m
Mar 31 2022	n/a	n/a	-CA$9m
Dec 31 2021	n/a	n/a	-CA$10m
Sep 30 2021	CA$265k	CA$265k	-CA$11m
Jun 30 2021	n/a	n/a	-CA$11m
Mar 31 2021	n/a	n/a	-CA$12m
Dec 31 2020	n/a	n/a	-CA$10m
Sep 30 2020	CA$265k	CA$265k	-CA$9m
Jun 30 2020	n/a	n/a	-CA$9m
Mar 31 2020	n/a	n/a	-CA$9m
Dec 31 2019	n/a	n/a	-CA$8m
Sep 30 2019	CA$348k	CA$300k	-CA$8m
Jun 30 2019	n/a	n/a	-CA$7m
Mar 31 2019	n/a	n/a	-CA$7m
Dec 31 2018	n/a	n/a	-CA$7m
Sep 30 2018	CA$330k	CA$300k	-CA$7m
Jun 30 2018	n/a	n/a	-CA$7m
Mar 31 2018	n/a	n/a	-CA$7m
Dec 31 2017	n/a	n/a	-CA$6m
Sep 30 2017	CA$300k	CA$300k	-CA$6m
Jun 30 2017	n/a	n/a	-CA$6m
Mar 31 2017	n/a	n/a	-CA$5m
Dec 31 2016	n/a	n/a	-CA$5m
Sep 30 2016	CA$312k	CA$312k	-CA$5m

Compensación vs. Mercado: La compensación total de Andrew($USD399.88K) está por encima de la media de empresas de tamaño similar en el mercado Canadian ($USD174.55K).

Compensación vs. Ingresos: La compensación de Andrew ha aumentado mientras la empresa no es rentable.

CEO

Andrew Morris (57 yo)

2yrs

Permanencia

CA$543,040

Compensación

Mr. Andrew Morris is Chief Executive Officer of SQI Diagnostics Inc. from September 11, 2021 and Advisor to the board since June 05, 2023 and served as Director until June 05, 2023. He joined the SQI Diagn...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Andrew Morris	Advisor to the Board & CEO	2yrs	CA$543.04k	0.092% CA$ 5.6k
Morlan Reddock	CFO & VP of Administration	3.5yrs	CA$200.00k	sin datos
Eric Brouwer	Chief Scientific Officer & Advisor to the Board	5.9yrs	CA$350.00k	0.0049% CA$ 299.9
Peter Lea	Founder	24.7yrs	sin datos	sin datos
Tim McGough	Chief Commercial Officer	less than a year	sin datos	sin datos

3.5yrs

Permanencia media

57yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de SQD se considera experimentado (3.5 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Wilmot Matthews	Independent Director	8.4yrs	sin datos	23.03% CA$ 1.4m
Clive Beddoe	Independent Chairman of the Board	8.4yrs	sin datos	0.010% CA$ 612.6
Gerald Connor	Independent Director	8.4yrs	sin datos	24.5% CA$ 1.5m
Yehuda Shoenfeld	Chairman of Scientific Advisory Board	13.7yrs	sin datos	sin datos
Claude Ricks	Independent Director	16.3yrs	CA$4.00k	0.49% CA$ 29.9k
Eric Zwisler	Independent Director	5.3yrs	sin datos	sin datos

8.4yrs

Permanencia media

75.5yo

Promedio de edad

Junta con experiencia: La junta directiva de SQD se considera experimentada (8.4 años de antigüedad promedio).

SQI Diagnostics Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Clive J. Beddoe Announces Resignation as Director of SQI Diagnostics Inc

SQI Diagnostics Inc. Announces Executive Changes

SQI Diagnostics Inc., Annual General Meeting, Jun 30, 2023

Insufficient new directors

SQI Diagnostics Inc., Annual General Meeting, Apr 05, 2023

Independent Director recently sold CA$56k worth of stock

Recent updates

SQI Diagnostics Inc. Listing to Transfer to NEX Effective Feb. 20

Clive J. Beddoe Announces Resignation as Director of SQI Diagnostics Inc

SQI Diagnostics Expects its Common Shares to Continue to be Halted from Trading on Exchange and Ultimately Suspended and Delisted Following Completion of the Filing

SQI Diagnostics Inc. Announces Executive Changes

SQI Diagnostics Inc., Annual General Meeting, Jun 30, 2023

Second quarter 2023 earnings released: CA$0.009 loss per share (vs CA$0.007 loss in 2Q 2022)

Insufficient new directors

First quarter 2023 earnings released: CA$0.008 loss per share (vs CA$0.009 loss in 1Q 2022)

SQI Diagnostics Inc., Annual General Meeting, Apr 05, 2023

Full year 2022 earnings released: CA$0.048 loss per share (vs CA$0.031 loss in FY 2021)

SQI Installs Two Rali-Dx Systems in Toronto Hospitals to Fight the Growing Respiratory Health Crisis in Emergency Departments

SQI Diagnostics Inc. announced that it expects to receive CAD 1 million in funding

SQI Diagnostics Inc. announced that it expects to receive CAD 2 million in funding from Federal Economic Development Agency for Southern Ontario

SQI Diagnostics Announces Health Canada Approval of RALI-Dx Severity Triage Test

Third quarter 2022 earnings released: CA$0.012 loss per share (vs CA$0.002 loss in 3Q 2021)

Second quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

SQI Diagnostics (CVE:SQD) Has Debt But No Earnings; Should You Worry?

New York State Approves SQI Diagnostics' Exact Covid-19 Antibody Assay

First quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

SQI Diagnostics Systems Inc. signed a definitive agreement to acquire all of the assets underlying Precision Biomonitoring Inc businesses from Precision Biomonitoring Inc. for CAD 6.825 million

SQI Diagnostics Inc. announced that it expects to receive CAD 6 million in funding

Third quarter 2021 earnings released: CA$0.002 loss per share (vs CA$0.005 loss in 3Q 2020)

Is SQI Diagnostics (CVE:SQD) Weighed On By Its Debt Load?

FDA Stops Emergency Use Authorization Review of SQI Diagnostics Inc. RALI-Dx IL-6 Severity Triage Test for Covid-19 Patients

CEO & Director Robert Chioini has left the company

Second quarter 2021 earnings released: CA$0.011 loss per share (vs CA$0.009 loss in 2Q 2020)

Health Check: How Prudently Does SQI Diagnostics (CVE:SQD) Use Debt?

Independent Director recently sold CA$56k worth of stock

Are Insiders Buying SQI Diagnostics Inc. (CVE:SQD) Stock?

First quarter 2021 earnings released: CA$0.012 loss per share (vs CA$0.009 loss in 1Q 2020)

Director exercised options to buy CA$705k worth of stock.

Director recently bought CA$660k worth of stock

New 90-day high: CA$0.40

SQI Diagnostics Inc., Annual General Meeting, Mar 31, 2021

Full year 2020 earnings released: CA$0.032 loss per share (vs CA$0.045 loss in FY 2019)

Is SQI Diagnostics Inc. (CVE:SQD) Popular Amongst Insiders?

SQI Diagnostics Announces Patient Enrollment Begins for its COVID-19 HOME Antibody Test Clinical Study

New 90-day high: CA$0.28

Independent Director exercised options to buy CA$1.7m worth of stock.

If You Had Bought SQI Diagnostics (CVE:SQD) Stock A Year Ago, You Could Pocket A 246% Gain Today

Is SQI Diagnostics (CVE:SQD) Using Debt Sensibly?

Sqi Diagnostics Inc. Updates Clinical Progress on Novel Covid-19 Tests Under Development for U.S. Fda Regulatory Submission

Third quarter earnings released

SQI Diagnostics Inc. Announces Executive Changes

New 90-day high - CA$0.21

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad